Scarica l'app Stockscreener
985.08
0.80%
7.83
Dopo l'orario di chiusura:
984.01
-1.07
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
The Pill War Heats Up: Novo Relies On Wegovy To Reclaim Leadership From Eli Lilly - Emirates 24|7
Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more - Endpoints News
Harvest Fund Management Trims Eli Lilly Stake - National Today
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - AOL.com
Eli Lilly Stock Pulls Back from January Peak as Valuation Pressures Mount - AD HOC NEWS
Is Eli Lilly's Weight Loss Empire in Trouble? - AOL.com
Is Eli Lilly's Weight Loss Empire in Trouble? - The Motley Fool
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm - FinancialContent
Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit” - Insider Monkey
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPenKroger (NYSE:KR), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Boosts Chinese Manufacturing Investments - advancedmanufacturing.org
Kroger Says Eli Lilly's Zepbound KwikPen Now Available at Participating Pharmacies - marketscreener.com
Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program - 富途牛牛
Novo regained weight loss footing in the pill arena — but Lilly is coming - PharmaVoice
Form Health Joins the Lilly Employer Connect Platform - Business Wire
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm - The Globe and Mail
Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative - simplywall.st
Eli Lilly tops growth factor grades among S&P healthcare holdings (LLY:NYSE) - Seeking Alpha
Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November - Seeking Alpha
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs? - sharewise.com
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - Benzinga
Lilly Flags Safety Risk In Compounded GLP 1 - GuruFocus
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives - GuruFocus
Jim Cramer Answered Questions About 13 Stocks: Eli Lilly, Meta, and More - Insider Monkey
Eli Lilly finds impurity in compounded tirzepatide - Pharmaceutical Technology
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 - Insurance Journal
Health risk alert as weight-loss jab manufacturer issues warning - The Independent
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma
Eli Lilly to invest $125m in Japan plant to boost supply of new drugs - Nikkei Asia
Eli Lilly (LLY) Warns Against Compounded Tirzepatide Products - GuruFocus
KLCM Advisors Inc. Sells 5,592 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Issues Warning on Safety Concerns of Compounded Tirzep - GuruFocus
Roberts Capital Advisors LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Health: Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Gulf Daily News
Eli Lilly Expands China Production for Weight Management Drugs | 2026News and Statistics - IndexBox
Eli Lilly and Company finds impurity in compounded diabetes and obesity drug knockoffs - Traders Union
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Reuters
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly
Eli Lilly to invest USD 3bn in China - medwatch.com
PHARMARON Surges 12%+ After Reaching Production Co-op Agreement with Eli Lilly for Orforglipron - AASTOCKS.com
Pharmaron opens higher after reaching a production cooperation agreement for Orforglipron with Eli Lilly and Co. - 富途牛牛
Lilly to Invest $3 Billion in China to Boost Obesity Pill - Bloomberg.com
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia - The Manila Times
Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud - Law360
Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro - Insider Monkey
Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 - GuruFocus
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 - Fierce Pharma
Eli Lilly and Co (WAR:LILY) Construction In Progress : zł47,771 Mil (As of Dec. 2025) - GuruFocus
Lilly introduces direct-to-employer program for weight-loss drug - Indianapolis Business Journal
Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval - Pharmaceutical Technology
Eli Lilly (LLY) to Invest $3B in China for Weight Loss Drug Expa - GuruFocus
Eli Lilly's $3B China Investment for GLP-1 Drug Production | 2026News and Statistics - IndexBox
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there - Endpoints News
Eli Lilly (LLY) Submits Weight Loss Drug Application in China - GuruFocus
Wolfe bumps Eli Lilly target on oral obesity drug, cardiometabolic portfolio - Investing.com Nigeria
Eli Lilly and Co (WAR:LILY) Inventories, Raw Materials & Components : zł13,168 Mil (As of Dec. 2025) - GuruFocus
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound - Benzinga
Hims & Hers taps ex-Eli Lilly PR chief to lead communications - medwatch.com
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):